Orris
analyse_media
Reading File
Searching the Web

ACG clinical guideline Barrett's esophagus surveillance low grade dysplasia high grade dysplasia endoscopic eradication therapy

Searching PubMed

Barrett esophagus dysplasia surveillance

Finding Sources
Best current answer: 2 is incorrect.
High-grade dysplasia in Barrett's esophagus does not automatically require esophagectomy. After confirmation by an expert GI pathologist and careful endoscopic assessment, the usual treatment is endoscopic eradication therapy, typically resection of any visible lesion followed by ablation. Esophagectomy is reserved for selected situations, such as invasive cancer with higher-risk features or when endoscopic treatment is unsuitable. The updated ACG guideline recommends endoscopic eradication therapy for confirmed high-grade dysplasia.
A qualification for modern practice: statement 1 is also outdated. Nondysplastic Barrett's surveillance is generally every 3 to 5 years, adjusted for segment length, not automatically every 2 years. Confirmed low-grade dysplasia should be reviewed by an expert pathologist; ablation is generally preferred, while close surveillance remains an alternative.

Explain the current treatment algorithm for Barrett’s dysplasia

Reading File
Finding Sources
Finding Sources
Searching the Web

2023 ACG updated guideline Barrett's esophagus dysplasia management algorithm low grade high grade surveillance

Searching PubMed

Barrett esophagus dysplasia endoscopic eradication

Reading File

Current treatment algorithm for Barrett's dysplasia

1. Confirm the diagnosis first

Before deciding treatment:
  • Use high-quality endoscopy with careful inspection, targeted biopsies of any visible lesion, plus systematic four-quadrant biopsies.
  • Have any dysplasia diagnosis confirmed by an expert gastrointestinal pathologist, especially indefinite dysplasia and low-grade dysplasia.
  • Optimize reflux control, usually with a PPI. Lifestyle measures remain appropriate for symptom control, but they do not replace dysplasia-directed treatment.
The need for expert review matters because low-grade dysplasia is frequently downgraded on specialist pathology review. The ACG guideline emphasizes this before committing a patient to ablation.

Management by histology

FindingUsual management
Nondysplastic Barrett's esophagusPPI and surveillance, not ablation
Indefinite for dysplasiaIntensify acid suppression, repeat endoscopy and biopsies
Confirmed low-grade dysplasiaEndoscopic eradication therapy is generally preferred; surveillance is an acceptable alternative for selected patients
Confirmed high-grade dysplasiaEndoscopic eradication therapy
Intramucosal adenocarcinoma, T1aEndoscopic resection of visible lesion followed by eradication of residual Barrett's mucosa
Submucosal invasive cancer or high-risk pathologyMultidisciplinary staging and consideration of esophagectomy and/or oncologic therapy

2. Nondysplastic Barrett's esophagus

Do not routinely ablate.
  • Continue daily PPI if there is no contraindication.
  • Surveillance EGD:
    • Barrett's segment <3 cm: every 5 years
    • Segment ≥3 cm: every 3 years
These intervals presume a high-quality baseline examination with appropriate biopsies. ACG surveillance recommendations use Barrett's length to set the interval.

3. Indefinite for dysplasia

Inflammation from poorly controlled reflux can mimic dysplasia.
  1. Obtain expert pathology review.
  2. Optimize acid suppression, often twice-daily PPI.
  3. Repeat EGD with biopsies in about 6 months.
  4. Then:
    • If downgraded to nondysplastic Barrett's: use the nondysplastic pathway.
    • If low-grade dysplasia is confirmed: treat as LGD.
    • If still indefinite: perform annual surveillance.

4. Confirmed low-grade dysplasia

Preferred approach: endoscopic eradication therapy

For a patient with confirmed LGD and reasonable life expectancy, offer endoscopic eradication therapy (EET) to reduce progression to high-grade dysplasia or adenocarcinoma.
Sequence:
  1. Carefully inspect for visible or nodular lesions.
  2. Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection in selected lesions, because it provides definitive histologic staging.
  3. Ablate the remaining flat Barrett's segment, most commonly with radiofrequency ablation (RFA). Cryotherapy is an alternative in selected settings.
  4. Goal: complete eradication of intestinal metaplasia, not merely removal of the dysplastic focus.

Acceptable alternative: surveillance

Surveillance is reasonable if the patient declines EET, has competing comorbidity, or strongly prioritizes avoiding procedure-related risks.
  • Repeat EGD in 6 months, then at 12 months, then annually while LGD persists.
  • If no dysplasia is subsequently found, return to the nondysplastic surveillance schedule.
The choice should be shared decision-making after confirmation of LGD by an expert pathologist. ACG guidance on LGD supports either route, with EET generally favored.

5. Confirmed high-grade dysplasia

Treat with endoscopic eradication therapy, not routine upfront esophagectomy.
  1. Expert pathology confirmation.
  2. High-definition endoscopy at an experienced Barrett's center.
  3. Resect all visible lesions first with EMR or selected ESD.
  4. Ablate remaining flat Barrett's mucosa, usually RFA or cryotherapy.
  5. Continue surveillance after complete eradication.
Esophagectomy is now reserved for selected cases, for example:
  • Deep submucosal invasion
  • High-risk pathology after resection, such as poor differentiation or lymphovascular invasion
  • Endoscopically unresectable or extensive disease
  • Persistent or recurrent neoplasia unsuitable for further endoscopic therapy
  • Patient preference after informed discussion
This reflects the textbook position that EET is now the usual therapy for Barrett-associated mucosal neoplasia, while surgery remains appropriate in selected cases. Yamada's Textbook of Gastroenterology, p. 951.

6. T1a intramucosal adenocarcinoma

In carefully staged, endoscopically resectable T1a disease:
  • Perform EMR or ESD of visible cancer.
  • Assess depth, differentiation, margins, and lymphovascular invasion.
  • If pathology is favorable and disease is mucosal, ablate residual Barrett's mucosa.
  • Continue close surveillance.
T1a disease has a low enough lymph-node metastasis risk that endoscopic treatment is usually appropriate at experienced centers.

7. When endoscopic therapy is not enough

Refer for multidisciplinary evaluation, including surgical and oncology input, when there is:
  • Submucosal invasion, especially beyond superficial low-risk disease
  • Lymphovascular invasion
  • Poorly differentiated carcinoma
  • Positive deep margin after endoscopic resection
  • Suspicion of nodal or metastatic disease
  • Failure of endoscopic eradication
A recent systematic review of EMR and ESD for Barrett-associated neoplasia supports their central role in appropriate early lesions, though lesion selection and pathology are decisive (PMID 38942058).

Surveillance after successful eradication

Even after complete eradication of intestinal metaplasia, recurrence can occur.
If baseline was low-grade dysplasia:
  • EGD at 1 year
  • Then at 3 years
  • Then every 2 years
If baseline was high-grade dysplasia or intramucosal cancer:
  • EGD at 3 months
  • 6 months
  • 12 months
  • Then annually
Continue PPI therapy and inspect both the neosquamous esophagus and gastroesophageal junction carefully at follow-up.

Exam takeaway

Visible lesion = resect first. Flat residual Barrett's mucosa = ablate.
Confirm dysplasia with an expert pathologist, and reserve esophagectomy for invasive or high-risk disease rather than routine high-grade dysplasia.
This is a shared conversation. Sign in to Orris to start your own chat.